Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04579380
Recruitment Status : Recruiting
First Posted : October 8, 2020
Last Update Posted : February 2, 2021
Sponsor:
Information provided by (Responsible Party):
Seagen Inc.

Brief Summary:

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable).

All participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant.

The trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.


Condition or disease Intervention/treatment Phase
Uterine Neoplasms Uterine Cervical Neoplasms Biliary Tract Neoplasms Urologic Neoplasms Carcinoma, Non-Small-Cell Lung Breast Neoplasms Drug: tucatinib Drug: trastuzumab Drug: fulvestrant Phase 2

Detailed Description:

There are multiple cohorts in this trial:

  • 5 tumor specific cohorts with HER2 overexpression/amplification (cervical cancer, uterine cancer, biliary tract cancer, urothelial cancer, and non-squamous non-small cell lung cancer [NSCLC])
  • 2 tumor specific cohorts with HER2 mutations (non-squamous NSCLC and breast cancer)
  • 2 cohorts which will enroll all other HER2 amplified/overexpressed solid tumor types (except breast cancer, GEC, and CRC) or HER2-mutated solid tumor types.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 270 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Actual Study Start Date : January 11, 2021
Estimated Primary Completion Date : January 31, 2023
Estimated Study Completion Date : May 31, 2025


Arm Intervention/treatment
Experimental: Tucatinib + Trastuzumab (+ Fulvestrant)
Tucatinib + trastuzumab (+ fulvestrant in hormone-receptor positive HER2-mutant breast cancer only)
Drug: tucatinib
300 mg orally twice daily
Other Name: TUKYSA, ARRY-380, ONT-380

Drug: trastuzumab
Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1
Other Name: Herceptin

Drug: fulvestrant
Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.
Other Name: Faslodex




Primary Outcome Measures :
  1. Confirmed objective response rate (cORR) per investigator assessment [ Time Frame: From start of treatment up to approximately 2 years ]
    cORR is defined as the proportion of participants with best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1


Secondary Outcome Measures :
  1. Disease control rate (DCR) per investigator assessment [ Time Frame: From start of treatment up to approximately 2 years ]
    DCR is defined as the proportion of participants with confirmed CR, confirmed PR, or stable disease according to RECIST v1.1

  2. Duration of response (DOR) per investigator assessment [ Time Frame: From start of treatment up to approximately 2 years ]
    DOR is defined as the time from first documentation of objective response of confirmed CR or confirmed PR to the first documentation of disease progression per RECIST v1.1 or death from any cause, whichever occurs first.

  3. Progression-free survival (PFS) per investigator assessment [ Time Frame: From start of treatment up to approximately 2 years ]
    PFS is defined as the time from the date of treatment initiation to the date of disease progression according to RECIST v1.1 or death from any cause, whichever occurs first.

  4. Overall survival (OS) [ Time Frame: From start of treatment up to approximately 4 years ]
    OS is defined as the time from treatlemt initiation to death due to any cause.

  5. Incidence of adverse events (AEs) [ Time Frame: From start of treatment up to approximately 2 years ]
  6. Incidence of laboratory abnormalities [ Time Frame: From start of treatment up to approximately 2 years ]
  7. Incidence of dose alterations [ Time Frame: From start of treatment up to approximately 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Histologically or cytologically confirmed diagnosis of locally-advanced unresectable or metastatic solid tumor, including primary brain tumors
  • Participants with disease types other than breast cancer, biliary tract cancer, non-squamous NSCLC, and cervical cancer: Disease progression on or after the most recent systemic therapy for locally-advanced unresectable or metastatic disease
  • Participants with any breast cancer subtype:

    • Must have HER2-mutated disease which does not display HER2 overexpression/amplification
    • Must have progressed on or after ≥1 prior line of treatment (chemotherapy, endocrine therapy, or targeted therapy) for locally-advanced unresectable or metastatic breast cancer
    • Participants with metastatic HR+ HER2-mutated disease must have received a prior CDK4/6 inhibitor in the metastatic setting.
  • Participants with biliary tract cancer: must have completed ≥1 prior line of treatment (chemotherapy, endocrine therapy, or targeted therapy)
  • Participants with non-squamous NSCLC: has relapsed from or is refractory to standard treatment or for which no standard treatment is available
  • Participants with cervical cancer:

    • Participants with metastatic cervical cancer must have progressed on or after ≥1 prior line of systemic therapy in the metastatic setting.
    • Participants with locally advanced unresectable cervical cancer must have progressed on or after ≥1 prior lines of systemic therapy.
  • Disease demonstrating HER2 alterations (overexpression/amplification or HER2 activating mutations), as determined by local or central testing processed in a Clinical Laboratory Improvement Amendments (CLIA)- or International Organization for Standardization (ISO) accredited laboratory, according to one of the following:
  • HER2 overexpression/amplification from fresh or archival tumor tissue or blood
  • Known activating HER2 mutations detected in fresh or archival tumor tissue or blood
  • Have measurable disease per RECIST v1.1 criteria according to investigator assessment
  • Have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria

  • Participants with breast cancer, GEC, or CRC whose disease shows HER2 amplification/overexpression.
  • Previous treatment with HER2-directed therapy; participants with uterine serous carcinoma may have received prior trastuzumab
  • Known hypersensitivity to any component of the drug formulation of tucatinib or trastuzumab (drug substance, excipients, murine proteins), or any component of the drug formulation of fulvestrant in participants with HR+ HER2-mutated breast cancer
  • History of exposure to a 360 mg/m² doxorubicin-equivalent or >720 mg/m^2 epirubicin-equivalent cumulative dose of anthracyclines
  • Treatment with any systemic anti-cancer therapy, radiation therapy, or experimental agent within ≤3 weeks of first dose of study treatment or are currently participating in another interventional clinical trial.

There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04579380


Contacts
Layout table for location contacts
Contact: Seagen Trial Information Support 8663337436 clinicaltrials@seagen.com

Locations
Layout table for location information
United States, Arizona
Arizona Oncology Associates, PC - HAL Recruiting
Phoenix, Arizona, United States, 85016
United States, California
Pacific Shores Medical Group Recruiting
Long Beach, California, United States, 90813
United States, Washington
Northwest Cancer Specialists, P.C. Recruiting
Vancouver, Washington, United States, 98684
Sponsors and Collaborators
Seagen Inc.
Investigators
Layout table for investigator information
Study Director: Vicky Kang, MD Seagen Inc.
Layout table for additonal information
Responsible Party: Seagen Inc.
ClinicalTrials.gov Identifier: NCT04579380    
Other Study ID Numbers: SGNTUC-019
First Posted: October 8, 2020    Key Record Dates
Last Update Posted: February 2, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Seagen Inc.:
Cervical cancer
Uterine cancer
Biliary tract cancer
Gallbladder cancer
Cholangiocarcinoma
Urothelial cancer
Non-squamous non-small cell lung cancer
Non-squamous NSCLC
Breast cancer
Colorectal cancer
Ampullary cancer
Solid tumors
Solid tumors harboring somatic HER2 mutations
Seattle Genetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Breast Neoplasms
Carcinoma, Non-Small-Cell Lung
Uterine Cervical Neoplasms
Uterine Neoplasms
Biliary Tract Neoplasms
Urologic Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Digestive System Neoplasms
Biliary Tract Diseases
Digestive System Diseases
Trastuzumab
Fulvestrant
Antineoplastic Agents, Immunological
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Estrogen Receptor Antagonists